Research programme: anti-inflammatory therapeutics - TaiwanJ Pharmaceuticals

Drug Profile

Research programme: anti-inflammatory therapeutics - TaiwanJ Pharmaceuticals

Alternative Names: JKB-117; JKB-119

Latest Information Update: 29 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jenken Biosciences
  • Developer Jenken Biosciences; TaiwanJ Pharmaceuticals
  • Class Anti-inflammatories
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Nephritis; Pulmonary fibrosis; Rheumatoid arthritis

Most Recent Events

  • 29 Sep 2015 TaiwanJ Pharmaceuticals has patents pending for JKB 117 and JKB 119 in USA and other countries
  • 29 Sep 2015 Preclinical trials in Rheumatoid arthritis, Pulmonary fibrosis and Nephritis in Taiwan (unspecified route) before September 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top